Zyla Life Sciences
Zyla Life Sciences (ZCOR): 7 pipeline candidates · ~11 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
11.4 months
0% dilution
Lead: Approved
7 candidates
N/A
N/A
A transparent, data-derived signal for Zyla Life Sciencesacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$14.9M
Quarterly Burn
$7.5M
Runway
11.4 mo
Revenue
$19.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| egalet-002 | Preclinical |
| egalet-004 | Phase 1 |
| indocin | Approved |
| oxaydo | Approved |
| sprix | Approved |
| vivlodex | Approved |
| zorvolex | Approved |
Frequently asked questions
How many drug candidates are in Zyla Life Sciences's pipeline?
Zyla Life Sciences (ZCOR) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Zyla Life Sciences's lead drug candidate?
Zyla Life Sciences's most advanced tracked candidate is egalet-002 (Preclinical) for Pain.
What is Zyla Life Sciences's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Zyla Life Sciences has approximately 11.4 months of cash runway.
Who is the CEO of Zyla Life Sciences?
Assertio Therapeutics is the chief executive officer of Zyla Life Sciences (ZCOR).
Get the full picture on Zyla Life Sciences
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.